Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
13.45
Dollar change
+0.13
Percentage change
0.98
%
IndexRUT P/E- EPS (ttm)-3.10 Insider Own30.24% Shs Outstand61.73M Perf Week1.28%
Market Cap1.06B Forward P/E- EPS next Y-3.43 Insider Trans-0.00% Shs Float54.80M Perf Month17.36%
Income-192.80M PEG- EPS next Q-0.83 Inst Own70.23% Short Float22.58% Perf Quarter17.57%
Sales7.63M P/S138.47 EPS this Y-11.95% Inst Trans24.58% Short Ratio10.57 Perf Half Y-6.14%
Book/sh7.22 P/B1.86 EPS next Y-5.33% ROA-29.99% Short Interest12.37M Perf Year-32.75%
Cash/sh6.18 P/C2.18 EPS next 5Y- ROE-38.24% 52W Range8.22 - 21.42 Perf YTD-3.52%
Dividend Est.- P/FCF- EPS past 5Y- ROI-36.58% 52W High-37.21% Beta1.59
Dividend TTM- Quick Ratio14.41 Sales past 5Y0.00% Gross Margin-51.29% 52W Low63.63% ATR (14)0.81
Dividend Ex-Date- Current Ratio14.41 EPS Y/Y TTM-6.89% Oper. Margin-2844.03% RSI (14)58.02 Volatility4.43% 6.43%
Employees204 Debt/Eq0.17 Sales Y/Y TTM720.88% Profit Margin-2528.21% Recom1.40 Target Price45.89
Option/ShortYes / Yes LT Debt/Eq0.14 EPS Q/Q8.36% Payout- Rel Volume0.47 Prev Close13.32
Sales Surprise223.44% EPS Surprise20.42% Sales Q/Q235.52% EarningsNov 07 BMO Avg Volume1.17M Price13.45
SMA2011.46% SMA504.74% SMA200-7.54% Trades Volume547,093 Change0.98%
Date Action Analyst Rating Change Price Target Change
Apr-13-23Initiated Canaccord Genuity Buy $29
Feb-01-23Initiated Cantor Fitzgerald Neutral $21
Dec-15-22Initiated Goldman Sell $13
Oct-06-22Initiated Credit Suisse Neutral $48
Aug-25-22Upgrade Stifel Hold → Buy $32 → $56
Jun-17-22Initiated BMO Capital Markets Outperform $48
Feb-18-22Initiated RBC Capital Mkts Outperform $42
Sep-24-21Initiated Stifel Hold $58
Jul-12-21Initiated William Blair Outperform $92
Jul-12-21Initiated JP Morgan Neutral $50
Feb-13-24 06:05AM
Feb-12-24 08:30AM
Feb-01-24 06:30AM
Jan-31-24 12:28PM
Jan-17-24 12:04PM
04:38PM Loading…
Jan-11-24 04:38PM
Jan-04-24 08:00AM
Jan-02-24 06:30AM
Dec-29-23 12:00PM
09:55AM
Dec-13-23 09:55AM
Dec-06-23 12:31PM
Dec-01-23 04:00PM
Nov-28-23 10:37PM
04:01PM
09:55AM Loading…
Nov-27-23 09:55AM
Nov-20-23 04:26PM
Nov-17-23 03:41PM
Nov-16-23 05:41AM
05:20AM
Nov-13-23 07:20PM
04:03PM
02:28PM
12:17PM
12:07PM
08:56AM
Nov-12-23 03:30PM
10:34AM
Nov-09-23 09:55AM
08:00AM
05:57AM Loading…
05:57AM
Nov-07-23 07:56AM
06:36AM
06:30AM
Nov-06-23 08:02AM
Nov-01-23 07:06AM
05:40AM
Oct-31-23 07:09PM
04:04PM
06:01AM
05:00AM
Oct-30-23 03:46PM
08:30AM
Oct-25-23 01:45AM
Oct-23-23 07:38AM
06:30AM
Oct-10-23 09:45AM
Sep-27-23 07:49AM
Sep-26-23 06:30AM
Sep-21-23 04:05PM
Sep-18-23 06:30AM
Aug-31-23 10:30AM
Aug-11-23 09:10AM
Aug-10-23 07:50AM
06:40AM
06:30AM
Aug-03-23 06:30AM
Jul-25-23 09:55AM
Jul-13-23 09:53AM
Jun-16-23 06:02AM
Jun-15-23 04:07PM
06:30AM
Jun-09-23 08:02AM
Jun-01-23 06:30AM
May-23-23 06:30AM
May-15-23 07:45AM
06:36AM
06:30AM
May-11-23 07:21AM
May-09-23 06:30AM
Apr-20-23 06:24PM
Mar-31-23 12:04PM
Mar-27-23 06:30AM
Mar-04-23 07:32AM
Mar-03-23 06:30AM
Mar-02-23 06:30AM
Feb-15-23 09:00AM
Feb-14-23 06:30AM
Feb-06-23 09:35AM
Feb-01-23 02:10PM
Jan-30-23 07:10PM
Jan-03-23 04:05PM
Dec-24-22 06:13PM
Dec-20-22 01:51PM
Dec-15-22 11:20AM
Dec-05-22 04:13PM
12:28PM
Dec-02-22 05:04AM
Nov-17-22 01:58PM
Nov-14-22 02:31PM
Nov-11-22 06:30AM
Nov-10-22 05:00AM
Nov-09-22 12:35PM
Nov-07-22 04:14PM
02:03PM
11:13AM
07:45AM
06:30AM
Oct-31-22 04:02PM
08:49AM
Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan, Burt A. Adelman, and Barry Ticho in 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dorval AllisonChief Financial OfficerNov 29Sale11.455546,3434,060Dec 01 04:30 PM